溃疡性结肠炎(ulcerative colitis,UC)是一种以结肠黏膜及黏膜下层炎症为主要特征的慢性非特异性炎症,其致病机制复杂,易反复发作,现代医学研究认为其涉及氧化应激、免疫失衡等多方面因素。信号转导和转录激活因子3(signal transducer a...溃疡性结肠炎(ulcerative colitis,UC)是一种以结肠黏膜及黏膜下层炎症为主要特征的慢性非特异性炎症,其致病机制复杂,易反复发作,现代医学研究认为其涉及氧化应激、免疫失衡等多方面因素。信号转导和转录激活因子3(signal transducer and activator of transcription,STAT3)是调节细胞生长、分化和存活的重要因子,可被相关细胞因子激活,从而介导炎症、氧化应激及免疫反应以影响UC病理进程,并与核因子κB(nuclear factor kappa-B,NF-κB)、NOD样受体热蛋白结构域相关蛋白3(NOD-like receptor thermal protein domain associated protein 3,NLRP3)、细胞因子信号传导抑制因子(suppressor of cytokine signaling,SOCSs)等信号通路存在串扰现象。STAT3作为近年来UC相关研究的热点之一,本文综述了中药通过调控STAT3信号通路防治UC的研究进展,深入探究了STAT3激活及介导UC病理过程的分子机制,以及中药成分如何通过多途径调控STAT3信号通路,发挥其潜在的作用机制。相关研究揭示了中药通过调节STAT3信号通路,不仅有效抑制炎症、氧化应激的发生,还能在调控免疫反应、维持肠道屏障功能及完整性等方面发挥重要作用,有望为治疗UC提供新思路。展开更多
Breast cancer(BRCA)is characterized by high heterogeneity,with aggressive subtypes frequently showing poor prognosis and resistance to conventional therapies,making the discovery of new therapeutic targets and strateg...Breast cancer(BRCA)is characterized by high heterogeneity,with aggressive subtypes frequently showing poor prognosis and resistance to conventional therapies,making the discovery of new therapeutic targets and strategies imperative.Although elevated expression of discs large homolog 3(DLG3)has been reported in BRCA,its functional role in disease progression remains unclear.We performed bioinformatic analyses of clinical datasets to evaluate the prognostic significance of DLG3 expression in BRCA patients.In vitro gain-and loss-of-function experiments were conducted to assess the impact of DLG3 on BRCA cell proliferation,migration,and colony formation.Transcriptomic profiling,coupled with pharmacological inhibition,was employed to identify and validate downstream signaling pathways.Additionally,we extended our validation to an in vivo model to assess the role of DLG3 in tumor progression.We found that elevated DLG3 levels correlated with poor prognosis in breast cancer patients.Functionally,DLG3 overexpression significantly promoted cell proliferation and migration in estrogen receptor-positive MCF7 and triple-negative MDA-MB-231 breast cancer cells,whereas its knockdown suppressed these effects.Transcriptomic analyses revealed that DLG3 activates signal transducer and activator of transcription 3(STAT3)signaling,a finding further corroborated by Western blot.Critically,treatment with the STAT3 inhibitor Stattic attenuated DLG3-driven proliferation and migration,supporting a DLG3-STAT3 oncogenic axis.Furthermore,in vivo studies validated the role of DLG3 in promoting tumor growth and its correlation with elevated STAT3 signaling,consistent with our in vitro findings.Our findings establish DLG3 as a novel driver of breast cancer progression that directly activates STAT3 signaling.DLG3 thus represents both a potential prognostic biomarker and a promising therapeutic target for aggressive breast cancer subtypes,including triple-negative breast cancer.展开更多
文摘溃疡性结肠炎(ulcerative colitis,UC)是一种以结肠黏膜及黏膜下层炎症为主要特征的慢性非特异性炎症,其致病机制复杂,易反复发作,现代医学研究认为其涉及氧化应激、免疫失衡等多方面因素。信号转导和转录激活因子3(signal transducer and activator of transcription,STAT3)是调节细胞生长、分化和存活的重要因子,可被相关细胞因子激活,从而介导炎症、氧化应激及免疫反应以影响UC病理进程,并与核因子κB(nuclear factor kappa-B,NF-κB)、NOD样受体热蛋白结构域相关蛋白3(NOD-like receptor thermal protein domain associated protein 3,NLRP3)、细胞因子信号传导抑制因子(suppressor of cytokine signaling,SOCSs)等信号通路存在串扰现象。STAT3作为近年来UC相关研究的热点之一,本文综述了中药通过调控STAT3信号通路防治UC的研究进展,深入探究了STAT3激活及介导UC病理过程的分子机制,以及中药成分如何通过多途径调控STAT3信号通路,发挥其潜在的作用机制。相关研究揭示了中药通过调节STAT3信号通路,不仅有效抑制炎症、氧化应激的发生,还能在调控免疫反应、维持肠道屏障功能及完整性等方面发挥重要作用,有望为治疗UC提供新思路。
文摘Breast cancer(BRCA)is characterized by high heterogeneity,with aggressive subtypes frequently showing poor prognosis and resistance to conventional therapies,making the discovery of new therapeutic targets and strategies imperative.Although elevated expression of discs large homolog 3(DLG3)has been reported in BRCA,its functional role in disease progression remains unclear.We performed bioinformatic analyses of clinical datasets to evaluate the prognostic significance of DLG3 expression in BRCA patients.In vitro gain-and loss-of-function experiments were conducted to assess the impact of DLG3 on BRCA cell proliferation,migration,and colony formation.Transcriptomic profiling,coupled with pharmacological inhibition,was employed to identify and validate downstream signaling pathways.Additionally,we extended our validation to an in vivo model to assess the role of DLG3 in tumor progression.We found that elevated DLG3 levels correlated with poor prognosis in breast cancer patients.Functionally,DLG3 overexpression significantly promoted cell proliferation and migration in estrogen receptor-positive MCF7 and triple-negative MDA-MB-231 breast cancer cells,whereas its knockdown suppressed these effects.Transcriptomic analyses revealed that DLG3 activates signal transducer and activator of transcription 3(STAT3)signaling,a finding further corroborated by Western blot.Critically,treatment with the STAT3 inhibitor Stattic attenuated DLG3-driven proliferation and migration,supporting a DLG3-STAT3 oncogenic axis.Furthermore,in vivo studies validated the role of DLG3 in promoting tumor growth and its correlation with elevated STAT3 signaling,consistent with our in vitro findings.Our findings establish DLG3 as a novel driver of breast cancer progression that directly activates STAT3 signaling.DLG3 thus represents both a potential prognostic biomarker and a promising therapeutic target for aggressive breast cancer subtypes,including triple-negative breast cancer.
